There was a mistake in Figure 2D as published, where the representative images for U87 MG under the control and 10 nM Onalespib conditions were not accurately displayed. The corrected Figure 2D appears below.
Figure 2.
Colony formation and multicellular spheroid growth of U343 MG and U87 MG glioblastoma cells. Survival fraction of Onalespib and radiation treated U343 MG (A) and U87 MG (B) Survival fraction of Onalespib and radiation combination treatment of U343 MG (C) and U87 MG (D). Representative images of the colonies of the monotreatments and the combined treatments of Onalespib and radiation. Onalespib monotherapy and combination therapy with radiation in 3D spheroid model of U343 MG (E) and U87 MG (F). Graphs display the normalized spheroid volume (mm3) over time, (means ± standard deviation, n ≥ 3). LOEWE synergy scores for U343 MG (G) and U87 MG (I). Representative images of the U343 MG and U87 MG multicellular tumor spheroids at the endpoint of the assay are shown in (H, J), respectively. Data plotted as means ± standard deviation, n ≥ 3. One-way ANOVA with Tukey’s post-test ns (not significant), *(p < 0.05), **(p < 0.01), ***(p < 0.001) and ****(p < 0.0001).
There was a mistake in the caption of Figure 2 as published. The name of the cell line U343 MG was incorrectly spelled as “U434 MG and U34mg”. The corrected caption of Figure 2 appears below.
The original version of this article has been updated.
Footnotes
Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.